DRUG TRIAL News & Analysis

We take a closer look at the potential impact of remdesivir's nearly certain approval on our valuation model for Gilead.

Though Morningstar views the healthcare sectors in both the US and Australia as fairly valued overall, there is a handful of buying opportunities...

This ASX-listed biotech is working on a "blockbuster" cardiovascular product that has the potential to take its stock price to $250, says Morningstar...